The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins
Description
Ritonavir, originally developed as HIV protease inhibitor, is widely used as a booster in several HIV pharmacotherapy regimens and more recently in Covid-19 treatment (e.g., Paxlovid). Its boosting capacity is due to the highly potent irreversible
